OpenNashPodcasts

Person

David Ricks

David Ricks is the CEO of Eli Lilly, and this page collects what he said on one podcast, In Good Company with Nicolai Tangen, about weight-loss drugs, artificial intelligence in pharma and how drugs are developed. He said Eli Lilly and Novo Nordisk together serve fewer than 20 million people with obesity drugs, while perhaps a billion people are overweight or obese.

He also described how Lilly now takes about 2.5 years from idea to first human dose and about 5.9 years from first dose to approval. Other remarks cover access to new drugs in Europe and China, Lilly's direct-to-consumer pharmacy model, and his almost 29 years at the company. Each fact below has his exact quote and a link to the moment.

1 episodes · 28 quoted claims

David Ricks said Eli Lilly and Novo Nordisk together serve fewer than 20 million people with obesity drugs, while perhaps a billion people are overweight or obese.

“Because right now between Lilly and Novo Nordisk, we're maybe serving less than 20 million people on the planet.”

In Good Company with Nicolai Tangen · 0:05:21

David Ricks said obesity-related diseases such as cardiovascular, kidney and liver disease make up about 40% of health care costs in developed economies.

“those diseases make up about 40% of health care costs in developed economies.”

In Good Company with Nicolai Tangen · 0:04:46

David Ricks said that excluding Eli Lilly and Novo Nordisk, the pharmaceutical sector trades at about 12 times earnings, which he attributed to near-zero returns on R&D investment.

“If we take out the weight loss companies of Lilly and Novo from the sector, the sector trades at like 12 times earnings.”

In Good Company with Nicolai Tangen · 0:08:36

David Ricks said the industry average was about 10 years of clinical development plus four or five years of preclinical work, and Lilly in 2015 was slightly worse than average.

“is about 10 years in clinical development. So that's first human dose to approval in some market and about four or five years preclinically.”

In Good Company with Nicolai Tangen · 0:09:54

David Ricks said a 20-year drug patent leaves only about 10 to 12 years on the market after development time is used.

“our patent cycle is we get a 20 year patent, but once we exhaust all that time, we end up with like 10 or 12 years in market.”

In Good Company with Nicolai Tangen · 0:09:54

David Ricks said Eli Lilly now takes about 2.5 years from idea to first human dose and about 5.9 years from first dose to approval.

“It takes us about two and a half years to go from idea to first dose. And then about six years, last year, 5.9 years, to go from first dose to approval.”

In Good Company with Nicolai Tangen · 0:10:20

David Ricks said many biotechs wait for animal evidence before preparing production, whereas Lilly prepares production in parallel and stops if the drug fails.

“a lot of biotechs will wait till they get compelling preclinical evidence in animals their drug is working before they run production and figure out production to make doses for a first human study.”

In Good Company with Nicolai Tangen · 0:10:43

David Ricks said the number of possible drug-like molecules is on the order of 10 to the 60th, which is why Lilly uses generative AI for ideas.

“The chemical space is vast, like 10 to the 60th. So it's more stars than are in the universe kind of possibilities.”

In Good Company with Nicolai Tangen · 0:15:00

David Ricks said an AI-driven process improvement of about 8% at a key bottleneck let Eli Lilly ship roughly 7 to 8% more product in that production line.

“It allowed us to ship about 7 % or 8 % more product last year in that line.”

In Good Company with Nicolai Tangen · 0:16:03

David Ricks said Alzheimer's disease runs about seven years from diagnosis to death, which limits how fast a drug can be proven to work.

“Take like Alzheimer's disease. This is a seven-year process from diagnosis to death and we need to study a meaningful part of that to prove a medicine is working.”

In Good Company with Nicolai Tangen · 0:16:30

David Ricks said Eli Lilly typically submits to the US first, then Europe within weeks, and gets EU approval three to four months after US approval.

“we typically submit in the U.S. first and then within a few weeks into Europe. It's normal for us to have approval in Europe three to four months after.”

In Good Company with Nicolai Tangen · 0:18:23

David Ricks said Eli Lilly has discussed unequal patient access to new drugs across the EU's 27 member states with the European Parliament.

“We've had a lot of dialogue in the European Parliament about the access differences between the 27 member states.”

In Good Company with Nicolai Tangen · 0:19:14

David Ricks said China's delay in patient access to new drugs, once seven years, is now under 12 months, ahead of Europe's.

“Right now, that lag is coming down to less than 12 months. So already China has leapfrogged over Europe in the drug lag”

In Good Company with Nicolai Tangen · 0:20:14

David Ricks said China's formulary process runs on a calendar, so a drug launched early in January cannot be listed until the following January.

“So if you launch on January 5th, you actually cannot get on the formularies until January of the next year.”

In Good Company with Nicolai Tangen · 0:20:37

David Ricks said Eli Lilly's scientists have an average tenure of over 10 years, which he linked to the company's Indianapolis base.

“our average tenure for scientists at the company is over 10 years.”

In Good Company with Nicolai Tangen · 0:12:20

David Ricks said Eli Lilly has launched a direct-to-consumer pharmacy model in the US and four other markets.

“We've stood up in the US and now four other markets, a direct pharmacy model. So we're selling directly to consumers.”

In Good Company with Nicolai Tangen · 0:27:30

David Ricks said hip and knee replacements are slowing in populations using Eli Lilly's weight-loss drugs, which he cited as indirect value.

“So hip replacements and knee replacements are slowing in populations using our drugs.”

In Good Company with Nicolai Tangen · 0:32:44

David Ricks said Eli Lilly invented Prozac about 40 years ago and that as a generic it now costs about four or five cents a day in major markets.

“We invented Prozac 40 years ago. It's a standard of care globally for treating major depressive disorder. It costs in major markets about four or five cents a day.”

In Good Company with Nicolai Tangen · 0:33:18

David Ricks said a US Veterans Administration study involving Lilly found benefits of GLP-1 drugs for schizophrenia, major depressive disorder and alcoholism.

“There was an important study we were part of at the Veterans Administration in the U.S. that came out two weeks ago that looked at all these non-metabolic factors and showed benefits for schizophrenia, for major depressive disorder, for alcoholism, et cetera.”

In Good Company with Nicolai Tangen · 0:34:26

David Ricks said Lilly cut the time from phase three result to first regulatory submission from about half a year to days for Zepbound in obesity.

“it used to take us about half a year from when we got a phase three result to submit to the first regulator. And the last time we set a record, which was last year on ZepBound for obesity, it was measured in days.”

In Good Company with Nicolai Tangen · 0:46:59

David Ricks argued that combining the chair and CEO roles suits the pharmaceutical sector because of its long time horizon, with checks such as a lead independent director.

“I believe in our sector, because our time horizon is so long, there are benefits in uniting the role.”

In Good Company with Nicolai Tangen · 0:48:19

David Ricks said he has been at Eli Lilly almost 29 years and joined because his wife was studying medicine at Indiana University.

“I'm at Lilly 29 years almost now, and I joined the company for only one reason, because my wife was studying medicine at Indiana University and I needed a job in Indiana.”

In Good Company with Nicolai Tangen · 0:53:29

Eli Lilly's 2007 annual report cover featured a patient noting weight loss from a GLP-1 diabetes medicine, showing weight loss was noticed from the start.

“In fact, the cover of our annual report in 2007 has a woman who took this medicine and she said, my diabetes is under control and I'm losing a little weight.”

In Good Company with Nicolai Tangen · 0:01:55

According to David Ricks, weight loss was a design goal for tirzepatide but not for Lilly's earlier GLP-1 drugs such as exenatide and dulaglutide.

“It was a design goal for Trisepetide, which is these two actions for weight loss.”

In Good Company with Nicolai Tangen · 0:02:21

David Ricks said Eli Lilly is conducting large studies of its drugs for smoking cessation, citing smoking as a major problem particularly in Asia.

“Well, we know smoking is a very strong signal, and you'll see Lily this year conduct large studies in smoking cessation, which is still a major problem, particularly in Asia.”

In Good Company with Nicolai Tangen · 0:03:05

David Ricks said about two thirds of the roughly $3 billion cost of developing a drug is incurred in the phase three step, which Lilly gates with a contrarian review.

“When we do that, you mentioned the $3 billion, two thirds of that cost is the last step.”

In Good Company with Nicolai Tangen · 0:39:28